Robert James Thomas

Robert James Thomas

Auto-generated profile, based on publicly available information

Robert James Thomas

Loughborough University

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2011 in Biotechnology Letters
Verified
Journal Article
Open access
PDF file
CHChristopher J. Hewitt
Christopher J. Hewitt
KLKen Lee
Ken Lee
ANAlvin W. Nienow
Alvin W. Nienow
RTRobert J. Thomas
Robert J. Thomas
MSMark Smith
Mark Smith
CTColin R. Thomas
Colin R. Thomas
The effects on human mesenchymal stem cell growth of choosing either of two spinner flask impeller geometries, two microcarrier concentrations and two cell concentrations (seeding densities) were investigated. Cytodex 3 microcarriers were not damaged when held at the minimum speed, NJS, for their suspension, using either impeller, nor was there any observable damage to the cells. The maximum cell density was achieved after 8–10 days of culture with up to a 20-fold expansion in terms of cells per microcarrier. An increase in microcarrier concentration or seeding density generally had a deleterious or neutral effect, as previously observed for human fibroblast cultures. The choice of impeller was significant, as was incorporation of a 1 day delay before agitation to allow initial attachment of cells. The best conditions for cell expansion on the microcarriers in the flasks were 3,000 microcarriers ml−1 (ca. 1 g dry weight l−1), a seeding density of 5 cells per microcarrier with a 1 day delay before agitation began at NJS (30 rpm), using a horizontally suspended flea impeller with an added vertical paddle. These findings were interpreted using Kolmogorov’s theory of isotropic turbulence.

1 January 2005 in Cells Tissues Organs
Verified
Journal Article
Closed access
RTRobert J. Thomas
Robert J. Thomas
RBRena Bhandari
Rena Bhandari
DBDavid A. Barrett
David A. Barrett
ABAndrew J. Bennett
Andrew J. Bennett
JFJeffrey R. Fry
Jeffrey R. Fry
KSKevin M. Shakesheff
Kevin M. Shakesheff
In this study, we demonstrate the ability of a three-dimensional co-culture model to preserve some key aspects of differentiated hepatocyte function in vitro. Freshly isolated rat hepatocytes in co-culture with activated stellate cells rapidly aggregate to form well-defined viable spheroids. After 5 days in culture, the spheroids have a complex extracellular matrix support and hepatic ultrastructure including bile canaliculi, tight junctions, desmosomes and lipid storage. Co-culture spheroids have superior cytochrome P450 (CYP450) 3A and 2B function, and increased inducibility of 2B function, relative to a range of hepatocyte monoculture techniques (high-performance liquid chromatography of testosterone metabolites). Increased function in co-culture is supported by greater expression of CYP450 3A23, 1A2, and 2E1 mRNA relative to monoculture (reverse transcriptase quantitative polymerase chain reaction). Also, high hepatocyte growth factor mRNA expression in co-culture suggests a post-traumatic, or possibly regenerative, environment. A preliminary study of human hepatocytes co-cultured with rat stellate cells demonstrated prolonged function of CYP450 3A4, 2C19 and 2C9. This study shows that stellate cells facilitate spheroid formation, influence spheroid architecture, and are an effective method of preserving some aspects of hepatocyte function in the early stage of culture.

17 August 2011 in British Medical Bulletin
Verified
Journal Article
Open access
PDF file
LRLizzie Ratcliffe
Lizzie Ratcliffe
RTRobert J. Thomas
Robert J. Thomas
DWDavid J. Williams
David J. Williams
A novel manufacturing industry is emerging to translate unique cellular therapy bioprocesses to robust, scaled manufacturing production for successful clinical translation. This review summarizes key translational issues, and current and future perspectives to improve translation of cell-based therapy bioprocessing, based on literature search and author research. It is widely recognized that cell-based therapies could revolutionize health care for a range of diseases, and that there are gaps in the overarching framework and technologies to generate clinical success. There is limited understanding of how to fulfil requirements as regulatory and manufacturing guidelines are incomplete and few have achieved commercialization. Recent developments are encouraging adoption of automation and quality engineering approaches for bioprocessing of cell-based therapies. Include technology development to improve the cost and purity of manufacture and final product quality.

19 September 2007 in Cytotechnology
Verified
Journal Article
Open access
PDF file
RTRobert James Thomas
Robert James Thomas
ACAmit Chandra
Amit Chandra
YLYang Liu
Yang Liu
PHPaul C. Hourd
Paul C. Hourd
PCPaul P. Conway
Paul P. Conway
DWDavid J. Williams
David J. Williams
Tissue engineering and regenerative medicine are rapidly developing fields that use cells or cell-based constructs as therapeutic products for a wide range of clinical applications. Efforts to commercialise these therapies are driving a need for capable, scaleable, manufacturing technologies to ensure therapies are able to meet regulatory requirements and are economically viable at industrial scale production. We report the first automated expansion of a human bone marrow derived mesenchymal stem cell population (hMSCs) using a fully automated cell culture platform. Differences in cell population growth profile, attributed to key methodological differences, were observed between the automated protocol and a benchmark manual protocol. However, qualitatively similar cell output, assessed by cell morphology and the expression of typical hMSC markers, was obtained from both systems. Furthermore, the critical importance of minor process variation, e.g. the effect of cell seeding density on characteristics such as population growth kinetics and cell phenotype, was observed irrespective of protocol type. This work highlights the importance of careful process design in therapeutic cell manufacture and demonstrates the potential of automated culture for future optimisation and scale up studies required for the translation of regenerative medicine products from the laboratory to the clinic.

1 September 2008 in Journal of Biotechnology
Verified
Journal Article
Closed access
RTR.J. Thomas
R.J. Thomas
PHP.C. Hourd
P.C. Hourd
DWD.J. Williams
D.J. Williams

3 April 2009 in Biotechnology Letters
Verified
Journal Article
Closed access
PDF file
RTR. J. Thomas
R. J. Thomas
AHA. D. Hope
A. D. Hope
PHP. Hourd
P. Hourd
MBM. Baradez
M. Baradez
EME. A. Miljan
E. A. Miljan
DWD. J. Williams
D. J. Williams